IPO - Cidara Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-06-25

Corporate Action: Ipo

Type: New

Accession Number: 000119312525147004

Filing Summary: Cidara Therapeutics, Inc. is offering 7,954,546 shares of its common stock at a price of $44.00 per share, aiming to raise approximately $350 million. The offering follows the company’s recent announcement of positive results from its Phase 2b NAVIGATE trial for the prevention of seasonal influenza utilizing its lead asset, CD388. The company has provided the underwriters an option to purchase an additional 1,193,181 shares within 30 days from the date of the prospectus supplement. The net proceeds from the offering will support continued development and commercialization of pipeline assets, including CD388, alongside general corporate purposes. The company is identified as a 'smaller reporting company' under federal securities laws, allowing it to comply with reduced disclosure and reporting requisites. The assets are primarily targeted towards clinical development of CD388, for which Cidara reacquired rights from Janssen Pharmaceuticals after Janssen decided to halt its internal development of the drug in 2023. The offering is expected to amplify investor interest given the encouraging trial outcomes demonstrated by CD388, alongside the company's refined strategic focus following the divestment of its non-Cloudbreak asset, rezafungin. The shares are expected to be delivered on June 26, 2025, with risks associated highlighted for potential investors, including procedure-related uncertainties and market volatility.

Form Type: 8-K

Filing Date: 2025-06-25

Corporate Action: Ipo

Type: New

Accession Number: 000119312525147011

Filing Summary: On June 24, 2025, Cidara Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co. to conduct an underwritten public offering of 7,954,546 shares of its common stock at a public price of $44.00 per share. The offering is expected to generate approximately $350 million in gross proceeds before deductions. The offering will close on or about June 26, 2025, subject to customary closing conditions. The Underwriters have an option to purchase an additional 1,193,181 shares within 30 days. The agreement includes standard representations and conditions for closing. Additionally, press releases were issued announcing the commencement and pricing of the offering.

Form Type: CORRESP

Filing Date: 2024-12-30

Corporate Action: Ipo

Type: New

Accession Number: 000119312524286899

Filing Summary: Cidara Therapeutics, Inc. requested the U.S. Securities and Exchange Commission to take action for its Registration Statement on Form S-1, filed on December 23, 2024, to become effective on December 31, 2024, at 4:00 p.m. Eastern Time or as soon thereafter as practicable. This step is in preparation for an initial public offering, which indicates the company is advancing its efforts to raise capital in the public markets. The request was made through a formal communication addressed to the SEC, highlighting the company's intention to confirm the effective date post-approval with its legal counsel.

Form Type: S-1

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000119312524284233

Filing Summary: Cidara Therapeutics, Inc. has filed a registration statement with the SEC to offer up to $100 million in shares as part of an initial public offering (IPO). This opportunity is part of the company’s efforts to expand its capital base to support the development of its therapeutics pipeline, particularly focusing on its lead product candidate Rezafungin, which is aimed at treating serious fungal infections. The offering is underwritten by Cantor Fitzgerald, and the funds raised will also be used for the advancement of their research and development efforts. The company emphasizes its strategic partnerships with pharmaceuticals to enhance its market positioning and product delivery. Details regarding pricing, number of shares, and specific underwriter arrangements are expected to be provided in subsequent filings as the offering progresses.